Company intelligence / Profile preview

Zhengxu

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Zhengxu Biopharmaceutical is a China-based biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. The company leverages its proprietary mRNA technology platform to address unmet medical needs in infectious diseases and oncology. Founded by industry experts, Zhengxu focuses on optimizing mRNA sequences and delivery systems to enhance the efficacy and safety of its candidates. Its pipeline includes several programs aimed at viral infections and cancer immunotherapy. The company is headquartered in Suzhou Industrial Park, a major hub for life sciences innovation. Zhengxu aims to establish a full-chain mRNA drug development capability from sequence design to clinical production.

Therapeutic areas: Infectious DiseasesOncology
Modalities: mRNA-based drugsBiologicVaccineLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Zhengxu.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhengxu.

Explore the full profile